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Abstract 
Objectives 
Placental Growth Factor (PlGF) has been shown to be beneficial in diagnosing pre-eclampsia. We performed 
a prospective cohort study of revealed PlGF in standard clinical use in four teaching hospitals in UK, 
Germany, Austria and Australia. 
 
Study Design 
Clinical data from women with suspected pre-eclampsia or fetal growth restriction < 35 weeks’ gestation 
with revealed PlGF measurement were collected (MAPPLE study). 
 
Main Outcome Measures 
Data were compared to the PELICAN study (PlGF concealed). Pre-specified outcomes were compared using 
standard statistical tests (median difference or Risk Ratio). The results were further categorised by PlGF 
concentration: i) very low (<12pg/ml), ii) low (12-100pg/ml), iii) normal (>100pg/ml). 
 
Results  
396 women managed with revealed PlGF (MAPPLE) were compared with 287 women with concealed PlGF 
(PELICAN). Revealed PlGF led to delivery 1.4 weeks earlier (-2.0 to -0.9, 34.9 weeks vs 36.7 weeks). There 
were no significant differences in maternal adverse outcomes (11.9% vs 10.1%, Risk Ratio (RR) 1.17, 95%CI 
0.76-1.82) or caesarean sections (73.8% vs 64.5%; RR 1.14, 95%CI 1.03 to 1.26).  Revealed PlGF led to fewer 
perinatal deaths (2 vs 9; RR 0.16, 95%CI 0.03 to 0.74) and fewer babies with birthweight <3rd centile (28.9% 
vs 36.1%; RR 0.80, (0.65 to 0.99), but with more neonatal adverse outcomes (30.4% vs 17.1%; RR 1.78, 95%CI 
1.32 to 2.41). 
 
Conclusions 
Revealed PlGF may be associated with lower perinatal mortality and birthweight <3rd centile but appears to 
lead to earlier delivery with more neonatal respiratory morbidity. Randomised trials with adequate power 
for clinical outcomes are needed.  
 
Funding 
Financial assistance was received from Alere to support the running of the MAPPLE database. Alere had no 
access to the information or control over the database itself. 
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Highlights 
 We report PlGF-led management of pregnant women as part of routine clinical care 
 We compared our revealed PlGF cohort to a previous cohort with concealed PlGF results 
 Revealed PlGF leads to earlier delivery by 1.4 weeks 
 Revealed PlGF leads to fewer perinatal deaths and babies <3rd centile at birth 
 Revealed PlGF increased neonatal morbidity, predominantly due to respiratory causes 
  
  
Introduction 
Pre-eclampsia is a multisystem disorder affecting 3-5% of pregnancies and is associated with abnormal 
placentation and placental dysfunction (1). The detection of pre-eclampsia is a major focus of maternity care 
as it remains a significant cause of maternal and perinatal morbidity and mortality (1). The only treatment 
for pre-eclampsia currently available is delivery and therefore accurate diagnosis with the aid of a biomarker 
could allow adjustment to clinical care. 
 
Placental Growth Factor (PlGF) is one of several biomarkers which have been shown to have a predictive 
capacity for the screening and detection of pre-eclampsia (2, 3). PlGF is produced by the syncytiotrophoblast 
and is identifiable in maternal blood from as early as 12 weeks (4) with concentrations increasing with 
gestation until around 30 weeks before declining until birth (5). A decline in PlGF appears to represent a 
negative syncytiotrophoblast stress response to a variety of insults ranging from hypoxia (6), inflammation, 
oxidative stress(7) and is as such also seen as part of syncytiotrophoblast aging. PlGF concentrations are 
lower in pre-eclampsia (2), and extremely low in severe early-onset pre-eclampsia (8). Recently it has also 
been suggested that low PlGF concentrations are associated with fetal growth restriction (FGR) (9) and 
placental dysfunction (10). 
 
Currently the National Institute for Health and Care Excellence (NICE) (11) recommends the use of two 
platforms for PlGF assessment in pregnancy, produced by Alere (2) and Roche (12). The Alere platform uses 
antibodies against PlGF isoform-1, with some cross-reactivity for isoform-2, and has a moderate body of 
evidence for its clinical effectiveness at determining pre-eclampsia requiring delivery within 14 days 
(PELICAN study) (2, 13). The Roche platform, which measures soluble FMS‑like tyrosine kinase‑1 (sFlt‑1) 
relative to PlGF also has a developing body of evidence (PROGNOSIS study) (12). Both tests have been 
endorsed by NICE for the investigation of hypertension in pregnancy, to ‘rule out’ a diagnosis of pre-
eclampsia (11). Economic benefits, with savings of approximately £500 per patient, have also been 
suggested to be achievable if a PlGF based management pathway for women with hypertension in 
pregnancy is instigated (13). 
 
 
To date there have not been any published randomised controlled trials of the use of PlGF as a diagnostic 
test in women with hypertension in pregnancy. The best estimates of cost-effectiveness and clinical utility 
will come from randomised controlled trials such as the PARROT study (14). However, until these are 
available comparative cohort studies may offer an insight into the clinical impact of PlGF, when used as a 
diagnostic test in women presenting with suspected pre-eclampsia. The objective of the MAPPLE study was 
  
to report clinical outcomes in women managed with revealed PlGF results and to compare those outcomes 
with those of the PELICAN study (2) in which clinicians were not informed of the PlGF result. This would 
identify the potential clinical implications of revealing PlGF results to the clinician.  
 
Methods 
The Management of pregnancy complications with PIGF testing (MAPPLE) registry was established as a 
prospective cohort of women managed with revealed PlGF results according to local guidelines as part of 
clinical service evaluation. Four maternity units agreed to compile data on women with pregnancies 
complicated by suspected pre-eclampsia or fetal growth restriction managed with revealed PlGF as part of 
standard maternity care and funded from within maternity budgets. Participating units were located in the 
United Kingdom (Liverpool), Austria (Salzburg), Germany (Osnabrück) and Australia (Adelaide).  
A single 2.5ml whole blood sample was taken from each women into bottles containing ethylenediamine 
tetra-acetic acid. The plasma derived after centrifugation at 3000rpm for 5 mins was tested for PlGF 
concentration, using the Triage system (Alere, San Diego, CA), according to the manufacturer’s instructions. 
All meters were programmed throughout to produce a revealed PlGF result available immediately to 
laboratory and clinical staff. The assay uses fluorescently labelled recombinant murine monoclonal 
antibodies targeted to PlGF, which provide a quantifiable result within the range 12 to 3000pg/mL, within 
approximately 15 minutes. The manufacturer states a limit of detection of 9-3000pg/ml (11). 
 
Women presenting prior to 35 weeks’ gestation attending their local hospital with suspected pre-eclampsia 
or fetal growth restriction were offered PlGF testing in line with local hospital policy. No consent was 
required as PlGF informed management constituted routine care in these units. Clinicians were aware of the 
PlGF result and were expected to adjust care accordingly. An example of the PlGF guideline used at Liverpool 
Women’s Hospital can be found in Supplementary Text 1. 
 
Anonymised clinical data were entered onto a dedicated study case report form. A data transfer agreement 
was in place at each site before uploading to a secure database (Simplified Clinical Data Systems, 
Portsmouth, NH). The uploaded data were assessed for completeness by the lead author. Ethical permission 
was not required as no identifiable patient data were used.  
 
Data for clinical outcomes were compared, where possible, between revealed (MAPPLE) and concealed 
(PELICAN) cohorts (2) using median differences or risk ratios. Only the initial PlGF assessment was used even 
if more than one sample was taken to maintain consistency with the PELICAN study.  
 
  
The study is essentially a comparison of two cohorts of pregnant women, selected under different 
circumstances and for different reasons.  Accordingly, we decided to conduct an unadjusted comparison 
between the studies, which reported on all the important measures, and estimated the size of the 
differences and then to adjust comparisons for the principal differences between the women prior to PlGF 
testing.  Adjustment was made for maternal age, BMI, nulliparity, and proteinuria. For the adjusted analysis, 
women with twin pregnancies were excluded, as were women where key predictors were missing.  
When comparing event rates (e.g. perinatal deaths, perinatal adverse outcomes, results were expressed as 
odds ratios, with 95% confidence intervals. For the main continuous measures birthweight and gestational 
age at delivery, differences in the mean were calculated.  For additional measures, either means (with SD) or 
medians (with quartiles) were presented. Data are presented in the previously derived ranges of <12pg/ml 
(very low), 12-100pg/ml (low; representing <5th percentile of normal) and >100pg/ml (normal) (2, 10). 
Birthweights are presented as customised fetal weight centiles (15). We examined whether apparent 
differences in infant outcomes could be due to confounding at baseline ( maternal age, singleton pregnancy, 
ethnicity, pre-gestational diabetes, APS/SLE, previous pregnancy complications, new hypertension, 
suspected FGR and proteinuria) using multiple regression. We also compared the unadjusted and adjusted 
impact of revealed PlGF on management of pregnant women (antenatal steroid use, induction of labour, 
Caesarean section) using an interaction test.  
 
Results 
Between April 2014 and March 2016, clinical outcomes were obtained from 396 women presenting prior to 
35 weeks’ gestation with a known PlGF result and complete outcome dataset. The clinical datasets included 
for analysis came from Liverpool: 241 women; Osnabrück: 115 women; Salzburg: 26 women; Adelaide 14 
women.  
 
The MAPPLE cohort varied from the PELICAN cohort in a number of demographic features (maternal age, 
twin status, ethnicity, pre-gestational diabetes, APS/SLE, and complications of previous pregnancies) as 
shown in Table 1. The distribution of PlGF sub-groups at first sampling were similar.  
 
There were no significant differences in maternal adverse outcomes between women in the MAPPLE cohort 
compared to those in the PELICAN study (11.9% vs 10.1%, Risk Ratio 1.17; 95% confidence intervals 0.76 to 
1.82) with the majority of complications related to hepatic and renal dysfunction (Table 2).  
 
There were 433 babies in the MAPPLE cohort and 299 in PELICAN (Table 2). There was a single stillbirth 
within the MAPPLE cohort, in a woman with chronic hypertension with superimposed pre-eclampsia and 
  
severe early-onset FGR who withdrew from clinical care before presenting two weeks later with an 
intrauterine fetal death. There were significantly fewer perinatal deaths in the MAPPLE cohort (n=2, 0.5%) 
compared to those in the PELICAN study (n=9; 3.0%; Odds Ratio 0.16 (0.03 to 0.74). More babies 
experienced a composite perinatal adverse outcome in MAPPLE (n=133, 30.7%) than in PELICAN (n=61; 
20.4%; Risk Ratio 1.51 (1.15 to 1.98), Neonatal adverse outcomes were more common in the MAPPLE cohort 
(n=131; 30.4% vs. n=51; 17.1%; Risk Ratio 1.78 (1.32 to 2.41); these were dominated by respiratory 
morbidity including respiratory distress syndrome (RDS) and bronchopulmonary dysplasia (BPD). A higher 
proportion of babies in the MAPPLE cohort were admitted to the neonatal unit compared to those in the 
PELICAN study (n=190; 45.5% vs n=117; 39.8%; Risk Ratio 1.14 (0.95 to 1.37). 
 
The time between first PlGF test and delivery was shorter when PlGF result was revealed to the clinician with 
a mean difference of 6 days (-2.0 to -10.0; 24 days vs 29 days) (Table 3). A greater proportion of women with 
revealed PlGF (n=236; 59.9%) received antenatal steroids for fetal lung maturation compared to PELICAN 
(n=88; 30.1%; Risk Ratio 1.95; 1.61-2.37).  
 
Fewer women had fetal ultrasound assessment performed after PlGF sampling when PlGF was revealed 
(89.1% vs 98.7%; Risk ratio 0.90; 0.87 to 0.94) but the proportion of women with estimated fetal weight 
(EFW) <10th centile or abnormal fetal Doppler (absent or reversed end diastolic flow in the umbilical artery) 
was similar in both studies. There was no evidence of revealed PlGF testing affecting decisions to give 
steroids (p=0.09), induction of labour (0.13) or Caesarean section (0.18) assessed using interaction tests. 
Women with revealed PlGF results were delivered at an earlier gestation with a mean difference of 1.4 
weeks (-2.0 to -0.9, 34.9 weeks vs 36.7 weeks). There was an increased likelihood of the fetus being 
delivered by caesarean section in the MAPPLE cohort compared to the PELICAN cohort (73.8% vs 64.5%: Risk 
Ratio 1.14, 1.03 to 1.26). In women managed with revealed PlGF results, there was a significantly lower risk 
of women delivering a small for gestational age (SGA) infant <3rd centile (Risk Ratio 0.80; 0.65 to 0.99) 
compared to those managed with concealed PlGF results. 
 
Evaluation of principal outcomes in women with a singleton pregnancy (n=356 in MAPPLE; n=275 in 
PELICAN) with adjustment for baseline confounders did not substantially change the findings: mean 
gestation at delivery 34.4 (SD 3.6) vs. 36.0 (3.8) weeks; unadjusted median difference -1.33 (-1.89 to -0.77) 
and adjusted median difference -0.95 (-1.60 to -0.31) weeks; perinatal adverse outcomes 28.4% vs. 18.9%; 
uOR 1.74 (1.20 to 2.51) and aOR 1.51 (0.93 to 2.43). When analysis was restricted to singleton pregnancies, 
the increase in Caesarean sections was of borderline significance (uOR 1.39; 1.00 to 1.95) and the odds 
  
reduced (and not significant) when adjusted for baseline confounders between the cohorts (aOR 1.33; 0.85 
to 2.07).  
 
Tables 4 and 5 report maternal and perinatal outcomes for women managed with revealed and concealed 
testing by PlGF sub-group (<12, 12-100 and >100pg/ml). A greater proportion of women in the very low PlGF 
group in both cohorts had maternal adverse outcomes (compared to the other groups) and the interval from 
sampling to delivery was shortest in this group. As these two cohorts are not from a randomised 
comparison, and the cohort has been further divided, further statistical testing has not been undertaken.  
All stillbirths and perinatal deaths in revealed and concealed cohorts occurred in singleton pregnancies with 
abnormal PlGF concentrations (low or very low) (Table 5). Gestation at delivery was earliest in women with 
lowest PlGF concentrations, whether the result was revealed or concealed. 
 
Discussion 
In women managed with revealed PlGF results, there were fewer perinatal deaths; this may be due to 
modifications in surveillance and monitoring of these pregnancies than if the PlGF result were unknown. 
Previous observational cohorts have demonstrated a correlation between low PlGF concentrations at 19-24 
weeks’ gestation and subsequent stillbirth (16). Whilst around 25% of fetuses in both cohorts were identified 
as having an estimated fetal weight <10th centile on ultrasound at presentation, there were significantly 
fewer infants born small for gestational age (<3rd centile) in those managed with revealed PlGF results, even 
after adjustment for baseline predictors, suggesting that earlier delivery due to revealed PlGF may have 
prevented a slowing of fetal growth in utero. Revealing PlGF was associated with a shorter diagnosis to 
delivery interval and an earlier gestation at delivery. We observed a similar rate of antenatal diagnosis of 
SGA as the 15% observed in the sFlt1:PlGF study by Zeisler et al. (12). 
 
The revealing of PLGF to the clinical team was associated with a significant reduction in perinatal mortality. 
Not surprisingly this gain comes at the cost of increased neonatal unit admissions and perinatal morbidity, in 
particular respiratory complications. This higher prevalence of respiratory morbidity in the MAPPLE cohort 
may be related to the earlier gestation at delivery or increased use of caesarean delivery and was not 
ameliorated by an increased use of antenatal steroids. Diagnosis of respiratory distress syndrome and 
bronchopulmonary dysplasia was similar across centres within the MAPPLE study; it was higher than that in 
the PELICAN study and the 10% observed in the TRUFFLE cohort of growth restricted fetuses (who share 
many features with women in the PlGF <12pg/ml subgroup) (17).  
 
  
Around 10% of women in both cohorts had maternal adverse outcomes, similar to previous observations (2), 
with the majority of adverse outcomes other than abnormal biochemistry in women with very low PlGF 
concentrations. There was less preeclampsia in the revealed cohort perhaps suggesting that earlier 
intervention prevented a worsening of the maternal condition. However, women managed with revealed 
PlGF results required frequent attendance at antenatal clinic and admission, possibly due to the persistence 
of hypertension and other risk factors. 
 
This is the largest cohort study to date assessing the impact of PlGF informed care on pregnancy outcome 
and provides generalisable ‘real life’ data applicable across healthcare systems. At present these data 
provide the best information about the consequences of PlGF results in pregnancy. Outcomes have been 
compared between women managed with revealed results (MAPPLE) and those managed with concealed 
results (PELICAN) and variation in practice, differences in multiple pregnancy numbers or ethnicity between 
different countries could influence some of the outcomes.  Statistical comparison was limited to those least 
influenced by possible variations in practice.  
 
Our findings are  confirmed by the much smaller study by Cetin et al. (18), which assessed just 57 women 
with pre-eclampsia and 16 with fetal growth restriction.  
 
Conclusion 
Implication for practice 
Our data demonstrate that PlGF-informed management of high-risk pregnancies is feasible within standard 
clinical care. This study was not designed to demonstrate cost-effectiveness or perform an economic analysis 
of the use of PlGF, but previous assessments have suggested cost savings with PlGF use. Overall, our study 
suggests that early intervention with PlGF-led management may prevent worsening of fetal health but at the 
expense of earlier delivery and increased neonatal complications, almost exclusively due to respiratory 
morbidity, despite increased use of antenatal steroids. This may be offset by lower perinatal mortality and 
fewer small for gestational age babies. 
 
The statistically significant reduction in stillbirths between revealed and concealed PlGF led care is of interest 
but there should be caution in interpreting these data in light of the methodological differences between 
these two cohorts. Further evidence from randomised controlled trials will assist in interpretation of these 
findings. However, studies powered for stillbirth and perinatal death as an outcome are difficult to perform.  
The pattern of earlier delivery suggests that clinicians consider optimal management and timing of delivery 
in response to the knowledge of PlGF. However, earlier delivery (by six days) was also associated with 
  
worsened short-term neonatal outcomes; this may have been influenced by a lower gestation at enrolment 
in the revealed cohort and by the overall earlier gestation at delivery of 1.4 weeks. Education of obstetric 
teams and increased confidence in PlGF assessment over time to ensure that PlGF use leads to increased 
surveillance rather than precipitating delivery may optimise the benefit (i.e. reduced perinatal death) while 
limiting iatrogenic delivery. Likewise, the mode of delivery should be determined by accepted obstetrical 
indications rather than PlGF result alone. This should be considered when planning to introduce a new tests 
in a high risk population.   
 
Implications for research 
The nature of this study, with different cohorts, precludes more detailed interpretation of the results in table 
4 and 5. The true picture of potential clinical benefit or harm from PlGF-led management will only come 
from further randomised studies of its use as well as full cost-effectiveness assessment. Until the results of 
these studies are available, caution should be exercised before moving to PlGF-led management for all high-
risk women. Ongoing and future randomised studies should have adequate power to confirm or refute our 
findings. 
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Table 1: Demographic data and clinical characteristics at enrolment for women in MAPPLE (revealed PlGF 
testing) and PELICAN (concealed PlGF testing) cohort studies presenting prior to 35 weeks’ gestation. 
 
 MAPPLE (revealed 
PlGF testing) 
PELICAN (concealed 
PlGF testing) 
Risk Ratio 
 n=396 n=287  
Age (years; median, quartiles) 31 (27-35) 32 (27-36) -1.3 (-0.4 to -2.3) 
BMI (kg/m2; median, quartiles) 27 (24-32) 29 (24-34) -0.8 (-0.1 to -1.8) 
Nulliparous  208 (52.7) 164 (57.1) 0.92 (0.80 to 1.06) 
Singleton pregnancy  360 (90.9) 275 (95.8) 0.95 (0.91 to 0.99) 
Current Smoking  43 (11.3) 24 (8.6) 1.32 (0.82 to 2.12) 
Ethnicity: White 357 (91.1%) 187 (65.6%)  
Ethnicity: Black 12 (3.1%) 70 (24.6%) 0.12 (0.07 to 0.22) 
Ethnicity: Asian 8 (2.0%) 19 (6.7%) 0.24 (0.11 to 0.53) 
Ethnicity: Other 19 (4.8%) 11 (3.8%)  
Previous Medical History    
Previous Preeclampsia 87 (22.0) 55 (19.2) 1.15 (0.85 to 1.55) 
Chronic Hypertension 55 (14.4) 45 (15.7) 0.83 (0.58 to 1.19) 
Systemic Lupus Erythematosus/ 
Antiphospholipid syndrome 
6 (1.5) 12 (4.2) 0.34 (0.13 to 0.89) 
Pre-gestational diabetes 37 (9.3) 6 (2.2) 4.19 (1.79 to 9.79) 
Renal Disease 14 (3.5) 19 (6.6) 0.50 (0.26 to 0.98) 
Previous hypertensive disorder of 
pregnancy (excluding preeclampsia 
7 (1.8) 15 (5.6) 0.32 (0.13 to 0.77) 
    
Indication for PlGF testing (non-exclusive)    
New onset of hypertension 314 (79.5) 155 (54.0) 1.47 (1.31 to 1.66) 
Persistent epigastric/ right upper quadrant 
pain     
12 (3.0) 18 (6.3) 0.48 (0.24 to 0.99) 
Suspected fetal growth restriction 66 (16.7) 25 (8.7) 1.92 (1.24 to 2.96) 
Proteinuria 59 (14.9) 161 (56.1) 0.27 (0.21 to 0.34) 
    
Gestational age at sampling, (weeks; 
median, quartiles) 
30.7 (27.7-33.1) 31.0 (27.9-33.4) -0.1 (0.3 to -0.7) 
PlGF result at first testing     
PlGF <12 117 (29.5) 69 (24.0)  
PlGF 12-100 136 (34.3) 97 (33.8)  
PlGF >100 144 (36.3) 121 (42.2)  
 
  
  
Table 2: Maternal and perinatal adverse outcomes for women in MAPPLE (revealed PlGF testing) and 
PELICAN (concealed PlGF testing) cohort studies presenting prior to 35 weeks’ gestation with comparisons 
for major outcomes. 
 MAPPLE (revealed 
PlGF testing)  
PELICAN (concealed 
PlGF testing);  
Risk ratio 
 n=396 n=287  
Final diagnosis of pre-eclampsia (n, %) 193 (52.9) 176 (61.3) 0.86 (0.75 to 0.99) 
Women with maternal adverse outcomes (n, %) 47 (11.9) 29 (10.1) 1.17 (0.76 to 1.82) 
Maternal adverse outcomes (non-exclusive) (n)  55 36 - 
Maternal death 0 0 - 
Central nervous system    
Eclampsia 0 1 - 
Stroke; hypertensive encephalopathy 0 0 - 
Cortical blindness or retinal detachment 0 0 - 
Cardiovascular/ respiratory    
Myocardial infarction 0 0 - 
Intubation (other than for caesarean section) 0 1 - 
Pulmonary oedema 2  2 - 
Haematological    
Platelets <50×10⁹/L (without transfusion) 2 2 - 
Disseminated intravascular coagulation 1 1 - 
Thrombotic thrombocytopenic purpura/ 
haemolytic uraemic syndrome 
0 0 - 
Hepatic    
Dysfunction (Alanine transaminase ≥70IU/L)  38 23  
Haematoma; rupture; acute fatty liver of 
pregnancy 
1 0 - 
Renal    
Creatinine >150 μmol/L 7 2 - 
Dialysis 2 0 - 
Obstetric    
Placental abruption 1 4 - 
    
Number of infants n=433 n=299 Risk Ratio 
Infants with composite perinatal adverse 
outcome (perinatal death or neonatal adverse 
outcome) (n, %) 
131 (30.4) 60 (20.1) 1.51 (1.15 to 1.98) 
Perinatal death (n, %) 2 (0.5) 9 (3.0) 0.16 (0.03 to 0.74) 
Stillbirth (n, %) 1 (0.2) 7 (2.3) - 
Early neonatal death (n, %) 1 (0.2) 2 (0.7) - 
Infants with neonatal adverse outcomes (n, %) 131 (30.4) 51 (17.1) 1.78 (1.32 to 2.41) 
Neonatal adverse outcomes (non-exclusive) (n) 178  62 - 
Respiratory distress syndrome (n) 128 (30.5) 46 (15.4) - 
  
Bronchopulmonary dysplasia (n) 28 (6.7) 6 (2.0) - 
Intraventricular haemorrhage (Grade 3 or 4) (n) 4 (0.9) 0 (0.0) - 
Necrotising enterocolitis (n) 7 (1.7) 4 (1.3) - 
Retinopathy of prematurity (n) 11 (2.6) 6 (2.0) - 
Infants admitted to neonatal unit (n, %) 190 (45.5) 117 (39.8)  1.14 (0.95 to 1.37) 
 
  
  
Table 3: Impact of PLGF testing of the pregnancy management in women in MAPPLE (revealed PlGF 
testing) and PELICAN (concealed PlGF testing) cohort studies presenting prior to 35 weeks’ gestation 
 MAPPLE (revealed 
PlGF testing) 
PELICAN (concealed 
PlGF testing) 
Median Difference/ 
Risk Ratio 
Maternal  n=397 n=287  
Interval from first test to delivery 
(days; median, quartiles) 
24 (4 to 52) 29 (11 to 59) -6.0 (-2.0 to -10.0) 
Antenatal steroids (n, %) 236 (59.9) 88 (30.7) 1.95 (1.61 to 2.37) 
Induction of labour (n, %) 97 (24.5) 108 (37.6) 0.66 (0.52 to 0.82) 
    
Fetal  n=433 n=299  
Ultrasound scans (n, %) 384 (89.1) 295 (98.7) 0.90 (0.87 to 0.94) 
Estimated fetal weight <10th centile 
(n/N, %) 
80/375 (21.3) 83/285 (29.1) 0.73 (0.56 to 0.96) 
Absent or reduced end diastolic flow 
(umbilical artery Doppler (n/N, %) 
52/384 (13.5) 37/285 (13.1) 1.04 (0.70 to 1.54) 
    
Perinatal n=433 n=299  
Gestational age at delivery (weeks; 
median, quartiles) 
34.9 (32.0-37.1) 36.7 (33.6–38.6) -1.4 (-0.9 to -2.0) 
Caesarean section (n, %) 318 (73.8) 193 (64.5) 1.14 (1.03 to 1.26) 
Birthweight (grams; median, quartiles) 2280 (1490-2960) 2420 (1620–3125) -160 (-15 to -310) 
Small for gestational age infant <10th 
centile (n, %)  
181 (42.2)        145 (48.5) 0.87 (0.74 to 1.02) 
Small for gestational age infant <3rd 
centile (n, %) 
124 (28.9) 108 (36.1) 0.80 (0.65 to 0.99) 
 
  
  
Table 4: Maternal and fetal outcomes in women in MAPPLE (revealed PlGF testing) and PELICAN 
(concealed PlGF testing) cohort studies presenting prior to 35 weeks’ gestation presented by PlGF results 
at enrolment. 
 MAPPLE 
(revealed) 
PELICAN 
(concealed) 
MAPPLE 
(revealed) 
PELICAN 
(concealed) 
MAPPLE 
(revealed) 
PELICAN 
(concealed) 
 PlGF <12 PlGF <12 PlGF 12-100 PlGF 12-100 PlGF >100 PlGF >100 
Maternal  n=116 n=69 n=137 n=97 n=143 n=121 
Final diagnosis of pre-
eclampsia (n, %) 
51 (48.6) 67 (97.1) 69 (53.1) 72 ( 74.2) 73 (56.2) 37 (30.6) 
Women with any maternal 
adverse outcome (n, %) 
25 (21.6) 12 (17.4) 16 (11.7) 8 (8.2)   6 (4.2) 9 (7.4) 
Eclampsia 0 0 0 1 0 0 
Intubation  0 1  0 0 0 0 
Pulmonary oedema 1  2  1 0 0 0 
Platelets <50×10⁹/L  2  1  1 0 0 1 
Disseminated intravascular 
coagulation 
1  1  0 0 0 0 
Dysfunction (Alanine 
transaminase ≥70IU/L)  
23  9  11 7 4 7 
Creatinine >150 μmol/L 1 2 4 0 2 0 
Dialysis 0 0 1 0 1 0 
Placental abruption 1 3 0 0 0 1 
Interval from first test to 
delivery (median, quartiles) 
3 
(1 to 13) 
9  
(3 to 16) 
19 
(6 to 43) 
23  
(11 to 40) 
48 
(32 to 69) 
61  
(37 to 90) 
Antenatal steroids for fetal 
lung maturity (n, %) 
103 (89.6) 41 (59.4) 81 (59.6) 34 (35.1) 52 (36.4) 13 (10.7) 
Induction of labour (n, %) 10 (8.6) 13 (18.8) 35 (25.5) 44 (45.4)  52 (36.4) 51 (42.1)  
Antenatal clinic or 
assessment unit visits 
(mean, SD) 
2.5 (5.5) N/A 3.7 (5.3) N/A 5.2 (5.5) N/A 
Antenatal inpatient nights 
(mean, SD) 
2.3 (4.8) N/A 2.4 (5.8) N/A 3.8 (5.7) N/A 
       
Fetal n=122 n=69 n=158 n=105 n=151 n=125 
Number with ultrasound 
scans (n, %)  
111 (91.0)  68 (98.6) 146 (92.4)  104 (98.4) 127 (84.1)  123 (90.6) 
Estimated fetal weight 
<10th centile (n/N, %) 
50/109 
(45.9) 
43/68 
(63.2) 
17/142 
(12.0) 
28/99  
(28.3) 
13/124 
(10.5) 
12/118 
(10.2) 
Absent or reduced end 
diastolic flow in umbilical 
artery - Doppler (n/N, %) 
36/111 
(32.4) 
24/68 
(35.3) 
12/146  
(8.2) 
9/99  
(9.1) 
4/127 
(3.1) 
4/118  
(3.4) 
 
  
  
Table 5: Perinatal outcomes in MAPPLE (revealed PlGF testing) and PELICAN (concealed PlGF testing) 
cohort studies presenting prior to 35 weeks’ gestation presented by PlGF results at enrolment. 
 MAPPLE 
(revealed) 
PELICAN 
(concealed) 
MAPPLE 
(revealed) 
PELICAN 
(concealed) 
MAPPLE 
(revealed) 
PELICAN 
(concealed) 
 PlGF <12 PlGF <12 PlGF 12-100 PlGF 12-100 PlGF >100 PlGF >100 
Perinatal n=124 n=69 n=158 n=105 n=151 n=125 
Stillbirth (n, %) 1 (0.8) 4 (5.8) 0 3 (2.9) 0 0 
Neonatal death (n, %) 1 (0.8) 2 (2.9) 0 0 0 0 
Gestational age at delivery 
(weeks; median, quartiles) 
31.2 
(29.0-33.4) 
31.9  
(29.3-34.1) 
35.0 
(33.3-36.8) 
35.7 
(34.1-37.9) 
37.4 
(36.1-38.4) 
38.4  
(37–39.9) 
Delivery <37 weeks (n, %) 120 (100) 65 (94.2) 126 (79.7) 64 (60.1) 58 (38.4) 29 (23.2) 
Delivery <34 weeks (n, %) 97 (80.8) 50 (72.5) 48 (30.4) 23 (21.9) 22 (14.6) 10 (8.0) 
Caesarean section (n, %) 115 (94.3) 57 (82.6) 120 (75.9) 74 (70.5) 83 (55.0) 62 (49.6) 
Birthweight (grams; mean, 
SD) 
1360  
(970-1650) 
1280  
(862-1678) 
2290  
(1810-2740)  
2270  
(1757-2830) 
2990  
(2590-3355) 
3100  
(2672-3505) 
Small for gestational age 
infant <10th centile (n, %) 
92 (76.7) 57 (82.6) 65 (41.1) 59 (56.2) 24 (15.9) 29 (23.2) 
Small for gestational age 
infant <3rd centile (n, %) 
71 (59.2) 50 (72.5) 44 (27.8) 46 (43.8) 9 (6.0) 12 (9.6) 
Neonatal unit admission (n, 
%) 
94 (81.7) 53 (82.8) 71 (46.4) 46 (43.8)  25 (16.7) 18 (14.4) 
Infants with neonatal adverse 
outcomes (n, %) 
74 (60.7) 27 (39.1) 37 (23.4) 14 (13.3)  20 (13.2) 10 (8.0) 
Respiratory distress 
syndrome (n, %) 
72 (62.1) 23 (33.3) 36 (23.4) 14 (13.3)  20 (13.3) 9 (7.2) 
Bronchopulmonary dysplasia 
(n, %) 
19 (16.4) 6 (8.7) 4 (2.6) 0 5 (3.3) 0 
Intraventricular haemorrhage 
(Grade 3/4) (n, %) 
2 (1.6) 0 2 (1.3) 0 0 0 
Necrotising enterocolitis (n, 
%) 
4 (3.4) 3 (4.3) 2 (1.3) 0 1 (0.7) 1 (0.8) 
Retinopathy of prematurity 
(n, %) 
7 (6.0) 5 (7.2) 3 (1.9) 1 (1.0) 1 (0.7) 0 
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